Abstract

This study investigates factors influencing the cost of pharmacotherapy for primary hyperparathyroidism (PHPT) in a hospital setting to optimize therapeutic strategies and rationalize financing. The study was conducted from 2020 to 2023 and included 200 patients with PHPT from two hospitals in Moscow, Russia. The key aspects for analysis were demographic profiles, treatment methods, complications, and associated costs. The majority of patients (52.1%) were aged 60-74 years, while only 2.0% were aged 75 or older. The most frequently prescribed medications were cardiovascular drugs (33.5%) and vitamin supplements (25.1%). Colecalciferol (13.5%), bisoprolol (6.8%), and cinacalcet (4.9%) were the most common individual medications. The study revealed that the cost of conservative treatment without complications was twice that of surgical treatment. These models can aid in justifying and optimizing PHPT treatment financing in hospital settings. The findings highlight the importance of individualized treatment approaches and cost optimization strategies.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.